CSBR vs. DTIL, TSBX, GRTS, ELUT, TIL, PASG, GNTA, IKNA, CGTX, and ATHA
Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include Precision BioSciences (DTIL), Turnstone Biologics (TSBX), Gritstone bio (GRTS), Elutia (ELUT), Instil Bio (TIL), Passage Bio (PASG), Genenta Science (GNTA), Ikena Oncology (IKNA), Cognition Therapeutics (CGTX), and Athira Pharma (ATHA). These companies are all part of the "biological products, except diagnostic" industry.
Champions Oncology (NASDAQ:CSBR) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.
Champions Oncology has higher revenue and earnings than Precision BioSciences. Champions Oncology is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Champions Oncology had 44 more articles in the media than Precision BioSciences. MarketBeat recorded 48 mentions for Champions Oncology and 4 mentions for Precision BioSciences. Champions Oncology's average media sentiment score of 1.04 beat Precision BioSciences' score of -0.05 indicating that Champions Oncology is being referred to more favorably in the media.
Champions Oncology currently has a consensus price target of $7.50, indicating a potential upside of 57.23%. Precision BioSciences has a consensus price target of $60.00, indicating a potential upside of 509.76%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Champions Oncology.
Champions Oncology received 62 more outperform votes than Precision BioSciences when rated by MarketBeat users. However, 66.92% of users gave Precision BioSciences an outperform vote while only 60.08% of users gave Champions Oncology an outperform vote.
Champions Oncology has a net margin of -19.76% compared to Precision BioSciences' net margin of -125.84%. Precision BioSciences' return on equity of -204.66% beat Champions Oncology's return on equity.
Champions Oncology has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 45.7% of Champions Oncology shares are owned by company insiders. Comparatively, 5.1% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Champions Oncology beats Precision BioSciences on 10 of the 18 factors compared between the two stocks.
Get Champions Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Champions Oncology Competitors List
Related Companies and Tools
